Hamps Bio, a company involved in the marketing and distribution of pharmaceutical products and the manufacturing of freeze-dried and frozen goods, is tapping into both domestic and international markets. The company operates through a network of over 50 distributors and e-commerce platforms, with a focus on a variety of products ranging from pharma formulations to fruits, vegetables, and herbs.Hamps Bio’s initial public offering (IPO), which opened for bidding on Friday, December 13, is generating significant buzz. By 4:00 p.m. on the first day, the issue was subscribed 8.79 times, with retail investors driving the surge—seeing a massive 15.83 times subscription. The company plans to generate ₹6.22 crore via its IPO by issuing 12.22 lakh new shares, priced at ₹51 per share. The funds will go toward purchasing plant and machinery for its FMCG division, boosting brand visibility, and supporting general corporate expenses.